NICE-CF: Colon Cancer Screening for adults with Cystic Fibrosis Request More Information Trial Objective Adults with cystic fibrosis (CF) are at a higher risk of developing colon cancer due to a mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.. Because of the increased risk, doctors recommend adults with CF begin receiving colon cancer screenings at age 40 or at age 30 if they are post-transplant. The purpose of the NICE-CF clinical trial is to compare the results of an at-home, stool-based test (e.g., a fecal immunochemical test AND Cologuard® test) to that of a colonoscopy, which is considered the best way to identify colon cancer. If the stool-based test is as reliable as a colonoscopy, researchers are hoping the convenience of an at-home test will encourage more adults with CF to get screened for colon cancer. Participants will receive two at-home stool-based tests. Participants will be expected to complete a clinical colonoscopy as part of their routine standard of care. Enrollment This trial is active and currently recruiting. Who Can Participate Adults with CF ages 40-75 years old who have not had an organ transplant and are due for a colon cancer screening. Adults with CF ages 30-75 who have had an organ transplant and are due for a colon cancer screening. Age: 30-75 Gender: Any Gender Estimated Time Commitment Three to 12 months, depending on the completion of the at-home test and the colonoscopy Compensation Provided Trial Contact For more information, contact: Salma Moreno 303.270.2861 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Saint Louis University Principal Investigators Jeffrey King, MD + × Jeffrey King, MD Chief, Division of Gastroenterology Medical Director, GI Procedures Unit Associate Professor Department of Medicine View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Request More Information First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective Adults with cystic fibrosis (CF) are at a higher risk of developing colon cancer due to a mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.. Because of the increased risk, doctors recommend adults with CF begin receiving colon cancer screenings at age 40 or at age 30 if they are post-transplant. The purpose of the NICE-CF clinical trial is to compare the results of an at-home, stool-based test (e.g., a fecal immunochemical test AND Cologuard® test) to that of a colonoscopy, which is considered the best way to identify colon cancer. If the stool-based test is as reliable as a colonoscopy, researchers are hoping the convenience of an at-home test will encourage more adults with CF to get screened for colon cancer. Participants will receive two at-home stool-based tests. Participants will be expected to complete a clinical colonoscopy as part of their routine standard of care.